Biomarkers Market Size, Share, and Trends 2024 to 2034

Biomarkers Market Size, Share By Type (Validation, Efficacy, and Safety), By Disease (Neurological Diseases, Cancer, Immunological Diseases, Cardiovascular Diseases, and Others),By Application (Personalized Medicines, Drug Discovery & Development, Diagnostics, and Others) - Global Industry Analysis, Trends, Growth, Segment Forecasts, Regional Outlook 2024 - 2033

  • Last Updated : 13 Jun 2024
  • Report Code : 1182
  • Category : Healthcare

Biomarkers Market Size and Companies

The global biomarkers market size was USD 82.30 billion in 2023, accounted for USD 94.24 billion in 2024, and is expected to reach around USD 318.76 billion by 2033. The market is expanding at a solid CAGR of 14.5% over the forecast period 2024 to 2033.

Biomarkers Market Size 2024 to 2033

Biomarkers Market Key Takeaways

  • North America has held a revenue share of more than 45.18% in 2023.
  • By type, the safety segment has accounted revenue share of 37.9% of the total revenue in 2023.
  • By application, the drug discovery & development segment will dominate the market with a revenue share of 32.95% in 2023.
  • By disease, the cancer segment captured a revenue share of 36.8% in 2023.

U.S. Biomarkers Market Size and Growth 2024 to 2033

The U.S. biomarkers market size was estimated at USD 26.08 billion in 2023 and is predicted to be worth around USD 107.12 billion by 2033, at a CAGR of 15.2% from 2024 to 2033.

U.S. Biomarkers Market Size 2024 to 2033

North America is Estimated to be the Largest Market for Biomarkers

The research report covers key trends and prospects of biomarkers products across different geographical regions including North America, Europe, Asia-Pacific, Latin America, and Middle East and Africa. Geographically, biomarkers market is conquered by North America owing to high incidence of cancer and existence of state-of-the-art healthcare infrastructure. On the other hand, Asia-Pacific is anticipated to witness the rapid growth rate, on account of increasing research and development investment by major market players and initiatives taken by governments to boost the biopharmaceutical sector.

Biomarkers Market Share, By Region, 2023 (%)

Key market Insights:

Biomarkers have presented a major boost for early detection of cancer which can be a crucial development in the field of cancer diagnostics. Early detection can be a major advantage in the treatment and management of cancer. Biomarkers are vital as molecular markers of the physiological state of a cell at a definite time. Active genes, their corresponding protein products, and supplementary organic compounds produced by the cell generate these markers. As a regular cell progresses through the intricate process of transformation into a cancerous state, biomarkers can prove vital for the screening of early cancer and individuals at risk of evolving cancer. Consistent, non-invasive examinations for the early recognition of cancer improve the likelihoods for successful treatment and preclude the usage of an invasive biopsy.

Crucial factors accountable for market growth are:

  • Rising incidences of cancer
  • Increasing focus on establishment of biomarker-based diagnostic methods
  • Growing number of contract research organizations
  • High incidence of chronic ailments
  • Increasing research on use of biomarkers in early detection of cancer
  • Rapidly expanding applications of biomarkers in diagnostics

Biomarkers Market Scope

Report Highlights Details
Market Size in 2023 USD 82.30 Billion
Market Size in 2024 USD 94.24 Billion
Market Size by 2033 USD 318.76 Billion
Growth Rate  from 2024 to 2033 CAGR of 14.5%
Largest Market North America
Fastest Growing Market Asia Pacific
Base Year 2023
Forecast Period 2024 to 2033
Segments Covered By Type, By Application, and By Disease
Regions Covered North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa

 

Type Insights

Safety Biomarkers Segment Reported Foremost Market Stake in 2023

Safety Biomarkers segment recorded the prime market share in the global biomarkers market by type in 2023. Increasing use in the process of drug discovery is the major reason for high market share of safety biomarkers. Other factors such as increasing investment in research and development to develop new diagnostic procedures is expected to increase the usage of the safety biomarkers over the estimate period.

The efficacy biomarkers are projected grow at the highest CAGR during the forecast period mainly due to new product launches in the near future.

Disease Insights

Cancer is Projected to Dominate the Disease Segment of Biomarkers Market Revenue

Cancer is one of the most widely studied disorder in the world. Constant research in the cancer field has revealed that, use of biomarkers in early detection of the deadly disease can be a turning point in cancer management. Strong product pipeline of major manufacturers related to cancer biomarkers is expected to further boost the popularity of biomarkers in cancer management.

Neurological Diseases segment will expand at a significant CAGR during the forecast time-frame.

Application Insights

Drug Discovery & Development Projected to Dominate the Application Segment of Biomarkers Market Revenue

The use of biomarkers is on a constant rise in drug discovery and development majorly due to the advantages offered by biomarkers to scaleup the clinical development stage. These factors contribute to the growth of drug discovery & development segment.

Biomarkers Market Companies

  • Bio-Rad Laboratories, Inc.
  • Qiagen
  • Epigenomics AG
  • Abbott
  • Hoffmann-La Roche Ltd.
  • Agilent Technologies, Inc.
  • Johnson & Johnson Services, Inc.
  • Abbott
  • Siemens
  • Thermo Fisher Scientific, Inc.

Major Market Segments Covered:

By Type

  • Validation
  • Efficacy
  • Safety

By Disease

  • Neurological Diseases
  • Cancer
  • Immunological Diseases
  • Cardiovascular Diseases
  • Others

By Application

  • Personalized Medicines
  • Drug Discovery & Development
  • Diagnostics
  • Others

By Geography

    • North America
      • U.S.
      • Canada
    • Europe
      • Germany
      • France
      • United Kingdom
      • Rest of Europe
    • Asia Pacific
      • China
      • Japan
      • India
      • Southeast Asia
      • Rest of Asia Pacific
    • Latin America
      • Brazil
      • Rest of Latin America
    • Middle East & Africa (MEA)
      • GCC
      • North Africa
      • South Africa
      • Rest of Middle East & Africa

For questions or customization requests, please reach out to us at sales@precedenceresearch.com

Frequently Asked Questions

The global biomarkers market size was estimated at USD 82.30 billion in 2023 and is predicted to reach USD 318.76 billion by the end of 2033.

The global biomarkers market is growing at a CAGR of 14.5% from 2024 to 2033.

Biomarker (portmanteau of biological marker) is the attribute that is accurately measured and assessed as an indicator of regular biological processes, pathogenic procedures or pharmacological reaction to a therapeutic interference.

Factors such as high incidence of cancer, increasing focus on establishment of biomarker-based diagnostic methods, and growing number of contract research organizationsare driving the growth of biomarkers market.

In 2023, North America dominated the global market with a market share of more than 39%.

Safety Biomarkers segment recorded the prime market share in the global biomarkers market by type in 2023.

The use of biomarkers is on a constant rise in drug discovery and development majorly due to the advantages offered by biomarkers to scaleup the clinical development stage. These factors contribute to the growth of drug discovery & development segment.

The major companies functioning in the worldwide biomarkers market are Bio-Rad Laboratories, Inc., Epigenomics AG, Qiagen, Abbott, Johnson & Johnson Services, Inc., F. Hoffmann-La Roche Ltd., Agilent Technologies, Inc., Abbott, Siemens, and Thermo Fisher Scientific, Inc. among others.

Ask For Sample

No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client

Meet the Team

Deepa Pandey, one of our esteemed authors, plays a crucial role in shaping the high-quality content that defines our research reports. Deepa holds a Master's in Pharmacy with a specialization in Pharmaceutical Quality Assurance, equipping her with an in-depth understanding of the healthcare industry's regulatory, quality, and operational nuances. With 2+ years of experience in market research, Deepa has made

Learn more about Deepa Pandey

With over 14 years of experience, Aditi is the powerhouse responsible for reviewing every piece of data and content that passes through our research pipeline. She is not just an expert—she’s the linchpin that ensures the accuracy, relevance, and clarity of the insights we deliver. Aditi’s broad expertise spans multiple sectors, with a keen focus on ICT, automotive, and various other cross-domain industries.

Learn more about Aditi Shivarkar

Related Reports